Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
As of close of business last night, Jazz Pharmaceuticals plc’s stock clocked out at $127.75, up 1.28% from its previous closing price of $126.13. In other words, the price has increased by $1.28 from its previous closing price. On the day, 0.67 million shares were traded. JAZZ stock price reached its highest trading level at $128.1325 during the session, while it also had its lowest trading level at $125.56.
Ratios:
To gain a deeper understanding of JAZZ’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 4.64 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 6.13. For the most recent quarter (mrq), Quick Ratio is recorded 1.37 and its Current Ratio is at 1.62. In the meantime, Its Debt-to-Equity ratio is 1.47 whereas as Long-Term Debt/Eq ratio is at 1.18.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Deutsche Bank on July 15, 2025, initiated with a Buy rating and assigned the stock a target price of $152.
On March 07, 2025, UBS Upgraded its rating to Buy which previously was Neutral and also upped its target price recommendation from $145 to $179.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Aug 08 ’25 when Winningham Rick E bought 3,731 shares for $112.00 per share.
Kennedy Patrick bought 3,731 shares of JAZZ for $417,872 on Aug 08 ’25. On Aug 08 ’25, another insider, ENRIGHT PATRICK G, who serves as the Director of the company, bought 3,731 shares for $112.00 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, JAZZ now has a Market Capitalization of 7749161472 and an Enterprise Value of 11512360960. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.90 while its Price-to-Book (P/B) ratio in mrq is 2.09. Its current Enterprise Value per Revenue stands at 2.817 whereas that against EBITDA is 7.202.
Stock Price History:
The Beta on a monthly basis for JAZZ is 0.25, which has changed by 0.16858768 over the last 52 weeks, in comparison to a change of 0.16844666 over the same period for the S&P500. Over the past 52 weeks, JAZZ has reached a high of $148.06, while it has fallen to a 52-week low of $95.49. The 50-Day Moving Average of the stock is 11.63%, while the 200-Day Moving Average is calculated to be 7.17%.
Shares Statistics:
It appears that JAZZ traded 739.64K shares on average per day over the past three months and 741590 shares per day over the past ten days. A total of 60.64M shares are outstanding, with a floating share count of 57.71M. Insiders hold about 4.86% of the company’s shares, while institutions hold 102.32% stake in the company. Shares short for JAZZ as of 1755216000 were 5623440 with a Short Ratio of 7.60, compared to 1752537600 on 5726751. Therefore, it implies a Short% of Shares Outstanding of 5623440 and a Short% of Float of 10.7200004.
Earnings Estimates
The performance of Jazz Pharmaceuticals plc (JAZZ) in the stock market is under the watchful eye of 17.0 analysts actively contributing to its current rating.The consensus estimate for the next quarter is $5.74, with high estimates of $6.22 and low estimates of $5.17.
Analysts are recommending an EPS of between $5.6 and $4.89 for the fiscal current year, implying an average EPS of $5.3. EPS for the following year is $21.49, with 17.0 analysts recommending between $24.54 and $16.72.
Revenue Estimates
In the current quarter, 16 analysts expect revenue to total $1.11B. It ranges from a high estimate of $1.13B to a low estimate of $1.07B. As of the current estimate, Jazz Pharmaceuticals plc’s year-ago sales were $1.05BFor the next quarter, 16 analysts are estimating revenue of $1.16B. There is a high estimate of $1.22B for the next quarter, whereas the lowest estimate is $1.14B.
A total of 18 analysts have provided revenue estimates for JAZZ’s current fiscal year. The highest revenue estimate was $4.3B, while the lowest revenue estimate was $4.16B, resulting in an average revenue estimate of $4.22B. In the same quarter a year ago, actual revenue was $4.07BBased on 18 analysts’ estimates, the company’s revenue will be $4.48B in the next fiscal year. The high estimate is $4.92B and the low estimate is $4.17B.
